Restless legs syndrome remains one of the most undertreated neurological conditions, partly because the long-favored dopamine agonist medications carry a serious risk of augmentation — a paradoxical worsening of symptoms over time. Finding alternatives that sidestep this complication is a genuine clinical priority, and the cannabinoid system's role in modulating glutamate signaling in the striatum offers a mechanistically plausible new avenue.
This prospective, open-label exploratory trial enrolled 18 patients with RLS over a 12-week period, administering a fixed-ratio formulation of 2.7 mg THC combined with 2.5 mg CBD — a preparation already approved in some jurisdictions for spasticity in multiple sclerosis. Notably, 16 of the 18 participants had an underlying MS diagnosis, a population where RLS is substantially overrepresented. Investigators assessed outcomes using the International Restless Legs Syndrome Rating Scale (IRLS) as the primary endpoint, supplemented by actigraphy-measured sleep parameters and quality-of-life instruments at weeks 4 and 12. The cohort entered the trial with severe RLS scores at baseline, and dose titration was permitted at week 4 for insufficient responders.
While the excerpt stops short of reporting final efficacy data, several contextual points warrant attention. The striatal glutamate hypothesis for RLS has accumulated supportive neuroimaging evidence over the past decade, making cannabinoid inhibition of glutamate transmission a biologically grounded — not merely speculative — rationale. However, this study's most significant limitation is its design: open-label, single-arm, and small, with 16 of 18 patients sharing an MS diagnosis. That population-specific confound means findings cannot be readily generalized to idiopathic RLS, which comprises the majority of real-world cases. Additionally, the absence of a placebo comparator leaves substantial room for expectation bias in subjective symptom ratings. This is best characterized as a hypothesis-generating signal, warranting a properly powered, double-blind, randomized trial before clinical guidance can shift.